Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A V Patterson

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Biotechnology|August 24, 2010
uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954G A Prosser, A V Patterson, D F Ackerley
Cancer Research|July 14, 1998
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitroA V Patterson, D C Talbot, I J Stratford, et al.
Anti-Cancer Drugs|April 20, 2004
The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell linesJ Y Kim, A V Patterson, I J Stratford, et al.
British Journal of Cancer|March 5, 2004
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPTN A Helsby, D M Ferry, A V Patterson, et al.
Anti-Cancer Drug Design|October 2, 1998
Enzymology of tirapazamine metabolism: a reviewA V Patterson, M P Saunders, E C Chinje, et al.
British Journal of Cancer|February 22, 2000
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell lineM P Saunders, A V Patterson, E C Chinje, et al.
Gene Therapy|October 5, 2002
Novel chimeric gene promoters responsive to hypoxia and ionizing radiationO Greco, B Marples, G U Dachs, et al.
British Journal of Cancer|November 1, 1995
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)A V Patterson, H M Barham, E C Chinje, et al.
British Journal of Cancer|January 1, 1997
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069A V Patterson, M P Saunders, E C Chinje, et al.
British Journal of Cancer|December 10, 1999
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?E C Chinje, A V Patterson, M P Saunders, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Biotechnology|August 24, 2010
uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954G A Prosser, A V Patterson, D F Ackerley
Cancer Research|July 14, 1998
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitroA V Patterson, D C Talbot, I J Stratford, et al.
Anti-Cancer Drugs|April 20, 2004
The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell linesJ Y Kim, A V Patterson, I J Stratford, et al.
British Journal of Cancer|March 5, 2004
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPTN A Helsby, D M Ferry, A V Patterson, et al.
Anti-Cancer Drug Design|October 2, 1998
Enzymology of tirapazamine metabolism: a reviewA V Patterson, M P Saunders, E C Chinje, et al.
British Journal of Cancer|February 22, 2000
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell lineM P Saunders, A V Patterson, E C Chinje, et al.
Gene Therapy|October 5, 2002
Novel chimeric gene promoters responsive to hypoxia and ionizing radiationO Greco, B Marples, G U Dachs, et al.
British Journal of Cancer|November 1, 1995
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)A V Patterson, H M Barham, E C Chinje, et al.
British Journal of Cancer|January 1, 1997
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069A V Patterson, M P Saunders, E C Chinje, et al.
British Journal of Cancer|December 10, 1999
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?E C Chinje, A V Patterson, M P Saunders, et al.
Pageof 3